SUZHOU, China, and MÖLNDAL, Sweden, July 2, 2026
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, together with Madrigal Pharmaceuticals, have announced the successful completion of the first major milestone in their strategic collaboration to develop small interfering RNA (siRNA)-based therapies for metabolic dysfunction-associated steatohepatitis (MASH). The achievement marks an important step in advancing a novel RNA interference (RNAi) therapeutic candidate toward clinical development and reflects the companies’ shared commitment to addressing one of the most significant unmet medical needs in liver disease. Following the successful designation of the drug candidate, the collaboration will immediately transition into new preclinical studies designed to support planned clinical trials, accelerating the development timeline for innovative liver-targeted therapies. The partnership combines Ribo’s expertise in RNAi drug discovery, oligonucleotide chemistry, and targeted delivery technologies with Madrigal Pharmaceuticals’ leadership in MASH research and clinical development, creating a strong foundation for next-generation treatments aimed at slowing disease progression and improving patient outcomes.
Strategic Collaboration Accelerates RNAi Drug Development
The collaboration between Ribo and Madrigal Pharmaceuticals highlights the growing role of RNA interference (RNAi) technology in developing precision medicines for chronic liver diseases. Through their strategic partnership, both organizations are jointly advancing multiple preclinical research programs focused on identifying highly selective siRNA candidates capable of targeting disease-driving genes associated with MASH. Ribo contributes its vertically integrated RNAi discovery platform, proprietary delivery technologies, and extensive expertise in nucleic acid therapeutics, while Madrigal provides deep scientific knowledge and clinical experience in developing therapies for metabolic liver diseases.
Company leaders emphasized that the rapid achievement of the first development milestone demonstrates the complementary strengths of both organizations and their shared commitment to accelerating innovative treatment options for patients worldwide. The immediate initiation of additional drug studies further reflects the program’s positive momentum and readiness for future clinical evaluation.
Novel siRNA Therapies Target High Unmet Need in MASH
Advertisement
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can ultimately lead to cirrhosis, liver failure, and hepatocellular carcinoma if left untreated. Despite increasing global prevalence, significant unmet medical needs remain for therapies capable of effectively slowing or reversing disease progression. The collaborative program aims to develop liver-targeted siRNA therapeutics that selectively silence disease-related genes through RNA interference, offering the potential for highly specific and durable treatment effects while minimizing systemic exposure.
By expanding the range of RNA-based therapeutic approaches available for MASH, the collaboration seeks to complement existing treatment strategies and contribute to the growing field of precision medicine for chronic liver disorders. Successful advancement of these candidates could broaden therapeutic options for clinicians managing patients with progressive metabolic liver disease.
Milestone Strengthens Global RNA Therapeutics Innovation
The completion of this important development milestone reinforces the increasing global investment in RNA-based medicines, which continue to transform therapeutic approaches across multiple disease areas. Suzhou Ribo Life Science has established itself as a leading clinical-stage biotechnology company focused on RNA interference technologies, supported by comprehensive research, development, manufacturing, and delivery capabilities for oligonucleotide therapeutics. Through its subsidiary Ribocure Pharmaceuticals AB, the company is expanding the international development of innovative RNA medicines targeting diseases with significant unmet medical needs. Partnering with Madrigal Pharmaceuticals, a recognized leader in liver disease research, further strengthens the scientific and commercial potential of this collaborative program.
As the companies advance toward planned clinical studies, the partnership demonstrates how strategic collaborations combining RNAi platform technologies, drug discovery expertise, and clinical development capabilities are driving the next generation of precision therapies for complex metabolic diseases. The successful milestone not only accelerates development of a promising siRNA candidate for MASH but also reinforces the growing importance of RNA therapeutics in shaping the future of global biopharmaceutical innovation.
Source: Ribo Life Science press release
